Risk factors
Creative Medical Technology Holdings (CELZ) risk factors
Item 1A of every Creative Medical Technology Holdings, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors30 risks2 reworded
Annual cash use increased from $5.3 million to $5.9 million, and operating loss grew from $5.7 million to $6.1 million. Cash and short-term treasuries increased to $7.2 million backed by over $40 million in cumulative offerings.
Filed Mar 20, 2026 - FY2024 10-K risk factors30 risks
Creative Medical Technology Holdings faces ongoing financial losses and needs additional capital to fund its clinical trials. The company depends heavily on clinical execution for cell platforms like CELZ-201 and ImmCelz, along with third-party manufacturers and key executives.
Filed Mar 14, 2025